在阿尔茨海默氏症患者中评估电静脉扫描 (EVestG) 的诊断价值混合病理:试点研究
Zeinab A Dastgheib1, Brian J Lithgow1, Zahra K Moussavi1
1Diagnostic and Neurological Processing Research Laboratory, Biomedical Engineering Program, University of Manitoba, Riverview Health Centre, Winnipeg, MB R3L 2P4, Canada.
Medicina (Kaunas, Lithuania)
|December 23, 2023
概括
在一项试点研究中,电静脉扫描 (EVestG) 在区分阿尔茨海默病 (AD) 与混合AD和脑血管疾病 (AD-CVD) 中显示出有前途. 开发的算法在识别这些痴呆症亚型方面取得了很高的准确性.
科学领域:
- 神经科学是一个神经科学.
- 医学诊断 医学诊断 医学诊断
- 生物医学工程 生物医学工程
背景情况:
- 区分像阿尔茨海默氏症 (AD) 和脑血管疾病 (AD-CVD) 混合性痴呆症等痴呆症亚型是临床上具有挑战性的,因为症状重叠.
- 电静脉摄影 (EVestG) 正被探索为神经退行性疾病差异诊断的潜在的非侵入性工具.
研究的目的:
- 调查EVestG在区分AD,AD-CVD和健康对照人群中的有效性.
- 开发和评估一种新的分层多类诊断算法来分类这三个组.
主要方法:
- 使用来自AD,AD-CVD和对照组的EVestG数据开发了一个层次化的多类诊断算法.
- 该算法经过训练,随后在单独的盲目测试数据集上进行验证.
- 采用多变量分析来评估人口差异,控制年龄和性别.
主要成果:
- 诊断算法在训练组中达到85.7%的准确率,在盲测试组中达到79.6%.
- 在控制年龄和性别后,在人口之间发现了统计学上显著的差异.
- 最佳的EVestG特征是从对直坐和仰卧上/下刺激的反应中确定出来的.
结论:
- EVestG利用特定的刺激和特征,可以有效地区分AD,AD-CVD和健康的对照.
- 成功开发和验证了用于三向分类的层次诊断算法.
- 潜在的潜在机制涉及GABAergic抑制中断,影响EVestG反应.
相关概念视频
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...